(9265) Stock Price

Yamashita Healthcare Holdings is a holding company that manages its subsidiary group companies. Its core business is the sales of medical devices and related services. In addition to procuring and selling medical devices, the company also manufactures and sells medical devices, and leases and operates medical-related facilities.

The company's primary customers are medical institutions such as hospitals, clinics, and testing laboratories, with medical device sales forming the center of its revenue. In addition to selling equipment sourced from manufacturers, the company generates service revenue from maintenance and repairs, IT implementation support, materials management outsourcing (SPD), and consulting. The company also derives revenue from manufacturing and selling proprietary products and from rental income from medical malls.

The business consists of three main segments: "Medical Device Sales," "Medical Device Manufacturing and Sales," and "Medical Mall Operations." Sales are divided into five categories: general equipment, general consumables, minimally invasive treatment, specialized fields, and information and services. The company handles a wide range of products from diagnostic imaging equipment and endoscopes to various surgical instruments, consumables, medical information systems, and maintenance services. In manufacturing, the company produces proprietary products such as orthopedic implants. In the medical mall business, the company leases and manages facilities.

The company has established a three-year medium-term management plan beginning with the fiscal year ending May 2025, centered on "balanced management through aggressive investment and enhanced group capabilities." The targets for the final year, fiscal year ending May 2027, are consolidated net sales of 73 billion yen, consolidated operating profit of 950 million yen, operating margin of 1.3% or higher, and consolidated ordinary profit of 1 billion yen. The company also aims to enhance corporate value with targets of PBR of 1.0x or higher, ROE of 10% or higher, and dividend payout ratio of 30% or higher, seeking to balance growth investment with shareholder returns.

The company has designated human capital and logistics and information infrastructure as priority investment areas. Specifically, it will integrate personnel information across 10 group companies, including 9 operating subsidiaries, and establish a unified human resources system from recruitment through development. Additionally, the company will strengthen supply capacity through logistics center renovations and new logistics center initiatives, while expanding value-added services such as maintenance and support, business outsourcing for medical facilities, and medical information system implementation support to differentiate its offerings.

The company plans to accelerate expansion of business domains and entry into new markets through M&A and external partnerships. For promising new products, it will pursue early market penetration of intravenous infusion device rentals, injection compounding and audit support systems, and proprietary ultrasound diagnostic equipment. Revenue diversification will include minimally invasive treatment and diagnostic imaging equipment for medical institutions, as well as rental income from medical malls. While wage increases and higher logistics and R&D expenses are expected to pressure short-term profits, the company plans to control costs through productivity improvements and business digitalization.

The company positions technological innovation as a growth pillar and continues R&D investment. Through group-wide development capabilities, it will advance commercialization of products such as the ultrasound diagnostic imaging system "BreastScan," while promoting business process digitalization and information security enhancements to enable employees to focus on high-value-added work. Additionally, the company will practice ESG management emphasizing stable supply to local communities and business continuity (BCM), aiming to secure long-term competitiveness and trust.